Durect corporation announces pricing of $42.5 million public offering of common stock

Cupertino, calif., feb. 4, 2021 /prnewswire/ -- durect corporation (nasdaq: drrx) ("durect"), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its...
DRRX Ratings Summary
DRRX Quant Ranking